Arovella Therapeutics Limited ( (AU:ALA) ) has shared an update.
Arovella Therapeutics faced a setback when a private investor failed to fulfill a $15 million share subscription agreement, prompting the company to initiate a new capital raise. Despite the challenges, Arovella successfully secured $15 million from new investors, bolstering its cash position and enabling the continuation of its clinical trial for ALA-101. The funds will also support the development of other programs, reinforcing Arovella’s commitment to advancing its therapeutic pipeline.
More about Arovella Therapeutics Limited
Arovella Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative therapies for cancer treatment. The company is advancing its primary product, ALA-101, into clinical trials and is also working on expanding its pipeline to include solid tumor programs.
YTD Price Performance: -35.29%
Average Trading Volume: 1,538,648
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$117.1M
Learn more about ALA stock on TipRanks’ Stock Analysis page.